Conference Coverage
Conference Coverage
ILC: NAFLD a stealth trigger of hepatocellular carcinoma
Key clinical point: U.S. epidemiologic data link nonalcoholic fatty liver disease to a quarter of hepatocellular carcinoma cases. Major finding:...
Conference Coverage
ACOG: Practice and referral patterns may affect occult uterine sarcoma risk post hysterectomy
Key clinical point: Consider local clinical practice and referral patterns when counseling patients about occult uterine sarcoma risk. Major...
Conference Coverage
AACR: HPV vaccine may protect some women with prior exposure
Key clinical point: HPV vaccination provided strong protection at multiple anatomic sites in women without prior HPV exposure, and may still offer...
Conference Coverage
ASA: Radiation lowers local recurrence risk for DCIS patients with close or positive margins
Key clinical point: Ductal carcinoma in situ patients with close or positive tumor margins may benefit more from radiation. Major finding:...
Conference Coverage
Inhibitor may benefit certain ALL patients
In xenograft models of various ALL subtypes, ABT-199 produced an objective response rate below 30%. However, additional analyses unearthed...
Conference Coverage
Agent preferentially targets FLT3-ITD AML
PHILADELPHIA—Preclinical research suggests a novel agent has preferential activity in acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3...
Conference Coverage
Defining the role of TAMs in DLBCL
pseudopodia to engulf particles PHILADELPHIA—New research suggests the prognostic value of tumor-associated macrophages (TAMs) is disease-...
Conference Coverage
Reserve thrombophilia testing for select subgroups
Key clinical point: Clinicians should reserve thrombophilia testing for select subgroups of patients with venous thromboembolism. Major finding:...
Conference Coverage
VIDEO: Updating the immune response to nonmelanoma skin cancer
Conference Coverage
VIDEO: Larger lentigo maligna lesions increase risk
Conference Coverage
AACR: Targeted combo active in triple-negative breast cancer, ovarian cancer
Key clinical point: Combining the PARP inhibitor olaparib and the investigational P13K inhibitor BKM 120 is safe and active in triple-negative...